BIOMAT Database Logo BIOMAT Database Logo

Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity. 2014

Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
School of Chemistry and Chemical Engineering, Institute of Pharmaceutical Engineering, Southeast University, 87 Dingjiaqiao, Nanjing, Jiangsu 210096, PR China.

Two series of 20 novel 4-aminoquinazoline-urea derivatives have been designed and synthesized. The entire target compounds were investigated for their in vitro antiproliferative activity against six human cancer cell lines (K562, U937, A549, NCI-H661, HT29 and LoVo) using the MTT-based assay. Most compounds showed significant antiproliferative activities against four solid tumor cell lines, but no or poor activities against two leukemia cell lines. Furthermore, the target compounds were screened for Aurora A/B kinases inhibitory activity. Among them, 7c, 7d, 8c, and 8d are more potent against Aurora A kinase than ZM447439. Docking study of compounds 7d and ZM447439 revealed that they bound strongly to the ATP-binding sites of Aurora A and B. Thus, they may be promising lead compounds for the development of novel anti-tumor drug potentially via inhibiting Aurora kinases.

UI MeSH Term Description Entries
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001549 Benzamides BENZOIC ACID amides.
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol

Related Publications

Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Synthesis and antiproliferative properties of 4-aminoquinazoline derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity.
December 1998, Anti-cancer drug design,
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Synthesis and quantum chemical studies of new 4-aminoquinazoline derivatives as Aurora A/B kinase inhibitors.
March 2013, Chemical biology & drug design,
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity.
September 2021, Bioorganic & medicinal chemistry letters,
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
May 2019, European journal of medicinal chemistry,
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Novel 4-aminoquinazoline derivatives as new leads for anticancer drug discovery.
September 2015, Acta pharmaceutica (Zagreb, Croatia),
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Discovery of nitroaryl urea derivatives with antiproliferative properties.
August 2016, Journal of enzyme inhibition and medicinal chemistry,
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
January 2009, Journal of medicinal chemistry,
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Identification of 4-anilino-6-aminoquinazoline derivatives as potential MERS-CoV inhibitors.
October 2020, Bioorganic & medicinal chemistry letters,
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors.
January 2014, ChemMedChem,
Jin Cai, and Lili Li, and Kwon Ho Hong, and Xiaoqing Wu, and Junqing Chen, and Peng Wang, and Meng Cao, and Xi Zong, and Min Ji
Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors.
March 2019, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!